measureName,measureId,submissionMethod,measureType,standardDeviation,averagePerformanceRate,isToppedOut,isToppedOutByProgram,percentile1,percentile10,percentile20,percentile30,percentile40,percentile50,percentile60,percentile70,percentile80,percentile90,percentile99,isHighPriority,isInverse,metricType
Screening Coronary Calcium Scoring for Cardiovascular Risk Assessment Including Coronary Artery Calcification Regional Distribution Scoring,MSN13,QCDR Measure,Process,25.974715439464816,90.58,Yes,Yes,0.35,67.31,99.485,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,N,registrySinglePerformanceRate
DEXA/DXA and Fracture Risk Assessment for Patients with Osteopenia,QMM19,QCDR Measure,Process,32.59332206811633,78.47,Yes,Yes,5.97,18.41,39.83,78.0,91.44,100.0,100.0,100.0,100.0,100.0,100.0,N,N,registrySinglePerformanceRate
Lung Cancer Reporting (Resection Specimens),396,MIPS CQM,Process,0.5485051113188069,99.95,Yes,No,84.0,86.0,88.0,90.0,92.0,94.0,96.0,98.0,99.0,100.0,100.0,Y,N,singlePerformanceRate
Breast Cancer Screening,112,eCQM,Process,26.544685931918426,56.08,No,No,0.18,9.48,32.76,46.11,55.16,62.6,68.22,73.37,78.9,85.59,99.35,N,N,singlePerformanceRate
Initiation and Engagement of Substance Use Disorder Treatment,305,eCQM,Process,7.951677569543225,7.20,No,No,0.41,1.56,2.44,3.19,4.44,5.185,6.19,7.5,9.6,13.78,51.61,Y,N,multiPerformanceRate
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention,226,MIPS CQM,Process,28.487791044192313,80.27,Yes,No,3.12,28.57,58.28,77.78,89.8,96.51,99.56,100.0,100.0,100.0,100.0,N,N,multiPerformanceRate
Use of Breast Cancer Risk Score on Mammography,QMM18,QCDR Measure,Process,35.40340979658916,77.83,Yes,Yes,0.01,1.39,57.48,75.84,95.0,99.29,100.0,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Optimizing Patient Exposure to Ionizing Radiation: Appropriateness: Follow-up CT Imaging for Incidentally Detected Pulmonary Nodules According to Recommended Guidelines,364,MIPS CQM,Process,22.529398881681225,90.03,Yes,No,84.0,86.0,88.0,90.0,92.0,94.0,96.0,98.0,99.0,100.0,100.0,Y,N,singlePerformanceRate
Urinary Bladder Cancer: Complete Analysis and Timely Reporting,CAP30,QCDR Measure,Process,13.13256859252224,86.61,No,No,55.25,65.9,73.6,81.6,84.29,90.925,95.58,97.06,99.51,100.0,100.0,Y,N,registrySinglePerformanceRate
Antiemetic Therapy for Low- and Minimal-Emetic-Risk Antineoplastic Agents in the Infusion Center - Avoidance of Overuse (Lower Score - Better),PIMSH15,QCDR Measure,Process,13.51695671864776,32.10,No,No,7.5,14.0,21.1,26.5,28.0,31.65,34.2,37.9,42.9,50.0,71.9,Y,Y,registrySinglePerformanceRate
Coronary Artery Disease (CAD): Beta-Blocker Therapy – Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF ≤ 40%),007,eCQM,Process,10.619104258114433,86.99,No,No,38.28,76.0,81.82,85.34,88.0,89.66,91.03,92.44,94.12,96.0,100.0,N,N,singlePerformanceRate
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention,226,Medicare Part B Claims,Process,17.9588614068234,92.93,Yes,Yes,8.57,75.95,93.33,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,N,multiPerformanceRate
Psoriasis: Clinical Response to Systemic Medications,410,MIPS CQM,Outcome,22.16310193279443,87.43,No,No,9.68,55.13,77.14,90.36,96.55,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Colonoscopy Interval for Patients with a History of Adenomatous Polyps - Avoidance of Inappropriate Use,185,MIPS CQM,Process,14.653894574795597,94.99,Yes,Yes,24.39,89.29,96.18,99.18,99.83,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Total Knee or Hip Replacement: Shared Decision-Making: Trial of Conservative (Non-surgical) Therapy,350,MIPS CQM,Process,30.861134810536175,87.21,Yes,Yes,0.25,15.77,99.17,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Appropriate Antiemetic Therapy for High- and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center,PIMSH16,QCDR Measure,Process,10.763446610901939,83.59,No,No,53.5,68.8,74.1,78.0,82.4,85.35,87.6,90.1,93.3,96.6,100.0,N,N,registrySinglePerformanceRate
Low dose cancer screening recommendation for computed tomography (CT) and computed tomography angiography (CTA) of chest with diagnosis of Emphysema.,QMM23,QCDR Measure,Process,41.52816862640552,61.41,No,No,0.44,2.815,12.27,19.0,48.935,86.72,99.2,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Stones: Repeat Shock Wave Lithotripsy (SWL) Within 6 Months of Initial Treatment,AQUA14,QCDR Measure,Outcome,9.027723254828727,7.62,No,No,0.0,1.06,1.77,2.76,4.0,5.355,6.7,7.73,9.38,11.9,39.58,Y,Y,registrySinglePerformanceRate
Oncology: Medical and Radiation - Pain Intensity Quantified,143,MIPS CQM,Process,11.94244440895922,95.95,Yes,No,84.0,86.0,88.0,90.0,92.0,94.0,96.0,98.0,99.0,100.0,100.0,Y,N,singlePerformanceRate
Unplanned Hospital Readmission within 30 Days of Principal Procedure,356,MIPS CQM,Outcome,9.903987901151424,2.89,No,No,0.0,0.0,0.0,0.0,0.0,0.0,0.775,1.96,3.03,5.36,77.13,Y,Y,singlePerformanceRate
Appropriate Emergency Department Utilization of CT for Pulmonary Embolism,ACEP22,QCDR Measure,Process,23.92739002209039,68.87,No,No,3.74,35.1,46.09,60.0,66.81,76.455,79.915,85.455,90.295,92.495,100.0,Y,N,registrySinglePerformanceRate
Benign Prostate Hyperplasia (BPH): Inappropriate Lab & Imaging Services for Patients with BPH,AQUA26,QCDR Measure,Process,9.346400150667503,3.07,Yes,Yes,0.0,0.0,0.0,0.0,0.0,0.0,0.73,2.13,4.04,5.855,58.54,Y,Y,registrySinglePerformanceRate
Psoriasis- Improvement in Patient-Reported Itch Severity,485,MIPS CQM,Patient-Reported Outcome-Based Performance Measure (PRO-PM),26.384138951738148,52.43,No,No,3.45,20.0,29.07,36.68,42.86,49.31,55.17,64.29,76.92,96.3,100.0,Y,N,singlePerformanceRate
Repeat screening or surveillance colonoscopy recommended within one year due to inadequate/poor bowel preparation,NHCR4,QCDR Measure,Process,16.877518265576782,83.06,No,No,39.53,56.52,67.14,83.08,84.85,89.61,91.32,93.85,95.83,98.81,100.0,Y,N,registrySinglePerformanceRate
Coronary Artery Disease (CAD): Antiplatelet Therapy,006,MIPS CQM,Process,14.306540957567254,89.51,Yes,Yes,40.79,69.63,78.26,85.37,91.67,96.945,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 20% OR Documentation of a Plan of Care.,141,Medicare Part B Claims,Outcome,0.0,100.00,Yes,Yes,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Complications After Cataract Surgery,IRIS54,QCDR Measure,Outcome,0.7897138967937961,0.41,No,No,0.0,0.0,0.0,0.0,0.0,0.15,0.29,0.48,0.76,1.12,2.7,Y,Y,registrySinglePerformanceRate
Antidepressant Medication Management,009,eCQM,Process,14.601121319569149,73.13,No,No,13.64,57.71,66.98,70.45,73.1,75.0,77.12,79.75,81.82,88.46,100.0,N,N,multiPerformanceRate
Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older,048,MIPS CQM,Process,21.092275180458312,90.56,Yes,Yes,2.88,63.64,90.46,97.88,99.6,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Appropriate Follow-up Imaging for Incidental Abdominal Lesions,405,MIPS CQM,Process,33.74072532203847,81.78,Yes,No,84.0,86.0,88.0,90.0,92.0,94.0,96.0,98.0,99.0,100.0,100.0,Y,N,singlePerformanceRate
Report Turnaround Time: Radiography,ACRAD15,QCDR Measure,Outcome,8.804144005618138,5.00,No,No,0.17,0.59,0.78,1.03,1.38,1.73,2.39,3.46,5.91,13.39,49.55,Y,Y,nonProportion
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD),005,MIPS CQM,Process,10.367822057832704,95.25,Yes,Yes,44.06,84.89,91.18,97.96,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Communication with the Physician or Other Clinician Managing On-Going Care Post-Fracture for Men and Women Aged 50 Years and Older,024,MIPS CQM,Process,29.356957426084016,80.87,Yes,No,1.69,34.19,57.625,77.15,92.495,95.83,99.89,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Avoidance of Opiates for Low Back Pain or Migraines,ECPR46,QCDR Measure,Process,5.874463899275924,94.83,Yes,Yes,77.42,85.0,92.08,94.04,96.62,97.11,98.09,98.67,98.78,99.99,100.0,Y,N,registrySinglePerformanceRate
Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients,320,Medicare Part B Claims,Process,0.0,100.00,Yes,Yes,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Colorectal Cancer Screening,113,eCQM,Process,26.812728945532836,49.80,No,No,0.12,5.71,23.98,36.1,45.9,53.535,60.33,67.16,73.82,83.55,97.83,N,N,singlePerformanceRate
Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation,012,eCQM,Process,27.414825520558594,80.03,No,No,1.55,33.82,62.32,80.36,88.75,93.295,96.08,97.76,99.09,100.0,100.0,N,N,singlePerformanceRate
Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy,268,MIPS CQM,Process,20.933686338773658,92.04,Yes,Yes,19.18,48.26,97.62,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Oncology: Patient-Reported Pain Improvement,PIMSH4,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),11.742042037664502,54.06,No,No,19.8,38.5,45.0,48.5,51.9,54.5,57.3,60.6,63.0,68.5,79.8,Y,N,registrySinglePerformanceRate
Kidney Health Evaluation,488,MIPS CQM,Process,29.982440735784824,50.58,No,No,1.63,19.28,25.35,30.41,37.86,40.82,49.46,65.93,88.64,98.2,100.0,N,N,singlePerformanceRate
Diabetes: Eye Exam,117,MIPS CQM,Process,15.621432210056785,94.57,Yes,Yes,16.51,85.69,97.14,99.53,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Dementia: Cognitive Assessment,281,eCQM,Process,31.9936838980329,44.60,No,No,0.53,4.0,10.0,19.64,29.94,40.84,52.17,67.02,79.31,93.04,100.0,N,N,singlePerformanceRate
Preventive Care and Screening: Unhealthy Alcohol Use: Screening & Brief Counseling,431,MIPS CQM,Process,34.42524238291447,72.85,No,No,1.29,11.22,33.67,60.0,78.75,93.9,99.53,100.0,100.0,100.0,100.0,N,N,multiPerformanceRate
Anastomotic Leak Intervention,354,MIPS CQM,Outcome,4.060602655656608,2.03,No,No,0.0,0.0,0.0,0.0,0.0,0.0,0.11,2.27,4.15,6.25,21.93,Y,Y,singlePerformanceRate
Cervical Cancer Screening,309,eCQM,Process,22.569987729438534,40.26,No,No,0.28,9.24,19.74,27.27,33.91,39.66,45.95,52.57,59.46,69.2,95.68,N,N,singlePerformanceRate
Overuse of Imaging for the Evaluation of Primary Headache,419,MIPS CQM,Process,3.4189023909673537,0.55,Yes,Yes,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.34,12.63,Y,Y,singlePerformanceRate
Multimodal Pain Management,477,MIPS CQM,Process,10.545050610741086,95.80,Yes,No,84.0,86.0,88.0,90.0,92.0,94.0,96.0,98.0,99.0,100.0,100.0,Y,N,singlePerformanceRate
Oncology: Medical and Radiation - Plan of Care for Pain,144,MIPS CQM,Process,21.45159355157709,88.67,Yes,Yes,6.25,64.19,84.075,91.73,97.315,98.97,99.76,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Safe Hydroxychloroquine Dosing,ACR15,QCDR Measure,Process,16.435443252948367,69.88,No,No,12.2,47.36,60.19,67.16,69.47,72.775,75.18,78.785,81.8,87.04,100.0,Y,N,registrySinglePerformanceRate
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention,226,eCQM,Process,31.421213244725845,63.13,No,No,3.23,16.39,28.59,42.05,55.26,67.74,80.91,90.62,97.14,100.0,100.0,N,N,multiPerformanceRate
Adult Primary Rhegmatogenous Retinal Detachment Surgery: Visual Acuity Improvement Within 90 Days of Surgery,385,MIPS CQM,Outcome,9.704393954149992,76.73,No,No,40.0,65.38,69.81,72.73,75.29,77.195,79.87,80.96,83.78,87.5,100.0,Y,N,singlePerformanceRate
Otitis Media with Effusion: Systemic Antimicrobials - Avoidance of Inappropriate Use,464,MIPS CQM,Process,20.20029850396085,90.29,Yes,No,3.41,74.22,87.65,92.86,96.15,98.37,99.64,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Falls: Plan of Care,155,MIPS CQM,Process,13.38582488814674,96.07,Yes,Yes,25.0,91.09,99.44,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Hepatitis B Safety Screening,ACR10,QCDR Measure,Process,18.77176507626213,56.87,No,No,3.23,32.81,40.0,49.06,54.26,58.9,64.49,68.94,72.93,77.42,94.9,Y,N,registrySinglePerformanceRate
"Functional Status Change for Patients with Elbow, Wrist or Hand Impairments",222,MIPS CQM,Patient-Reported Outcome-Based Performance Measure (PRO-PM),20.344596425569577,69.71,No,No,22.22,40.0,50.0,58.33,62.07,72.93,77.86,83.18,87.18,100.0,100.0,Y,N,singlePerformanceRate
Prevention of Post-Operative Nausea and Vomiting (PONV) - Combination Therapy,430,MIPS CQM,Process,6.425551323336801,98.65,Yes,No,84.0,86.0,88.0,90.0,92.0,94.0,96.0,98.0,99.0,100.0,100.0,Y,N,singlePerformanceRate
Oncology: Advance Care Planning in Metastatic Cancer Patients,PIMSH1,QCDR Measure,Patient Engagement/Experience,25.18623816532262,41.75,No,No,0.7,3.6,14.5,25.8,37.2,45.3,52.4,57.3,61.9,71.6,97.4,Y,N,registrySinglePerformanceRate
Intraocular Pressure Reduction Following Trabeculectomy or an Aqueous Shunt Procedure,IRIS39,QCDR Measure,Outcome,22.71289031253412,48.23,No,No,16.98,21.82,34.67,36.36,39.31,41.525,43.14,50.0,60.0,93.33,100.0,Y,N,registrySinglePerformanceRate
Allergic Rhinitis: Intranasal Corticosteroids or Oral Antihistamines,AAO23,QCDR Measure,Process,21.632789718582377,57.22,No,No,11.07,24.99,39.315,45.63,53.015,58.78,64.37,70.245,77.62,83.6,97.34,N,N,registrySinglePerformanceRate
Functional Status Change for Patients with Low Back Impairments,220,MIPS CQM,Patient-Reported Outcome-Based Performance Measure (PRO-PM),22.50429129784871,69.05,No,No,21.67,39.31,46.91,53.66,61.95,69.9,76.92,82.98,96.52,100.0,100.0,Y,N,singlePerformanceRate
Advance Care Plan,047,Medicare Part B Claims,Process,0.0,100.00,Yes,Yes,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Arteriovenous Fistulae Thrombectomy Clinical Success Rate,RPAQIR15,QCDR Measure,Outcome,12.761695787967026,83.83,No,No,37.1,70.0,80.0,81.08,85.0,87.82,88.89,90.91,92.45,94.37,97.44,Y,N,registrySinglePerformanceRate
Elder Maltreatment Screen and Follow-Up Plan,181,Medicare Part B Claims,Process,18.403016598740923,95.23,Yes,Yes,0.22,98.07,99.77,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Functional Status Change for Patients with Knee Impairments,217,MIPS CQM,Patient-Reported Outcome-Based Performance Measure (PRO-PM),22.841833666271818,70.74,No,No,22.22,39.39,47.85,56.56,63.58,71.68,79.03,84.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care,019,eCQM,Process,20.414469238658846,84.99,No,No,8.97,56.1,75.44,84.98,90.28,93.18,95.65,97.53,98.89,100.0,100.0,Y,N,singlePerformanceRate
Avoidance of Opioid therapy for dental pain.,ACEP62,QCDR Measure,Process,14.275463823061262,82.78,No,No,43.75,68.91,75.02,76.14,79.17,83.83,86.1,91.49,99.08,100.0,100.0,Y,N,registrySinglePerformanceRate
Oncology: Utilization of GCSF in Metastatic Colorectal Cancer,PIMSH2,QCDR Measure,Efficiency,17.93252595647047,23.37,No,No,0.0,3.8,8.6,13.0,18.2,20.15,24.1,26.1,36.0,51.2,72.0,Y,Y,registrySinglePerformanceRate
Report Turnaround Time: MRI,ACRAD17,QCDR Measure,Outcome,13.592191164334775,11.51,No,No,0.96,1.84,2.42,3.79,5.655,7.425,9.805,12.16,15.14,26.37,79.56,Y,Y,nonProportion
Unplanned Reoperation within the 30 Day Postoperative Period,355,MIPS CQM,Outcome,1.6051258516321643,0.48,No,No,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.4,1.54,6.06,Y,Y,singlePerformanceRate
Tobacco Use: Screening and Cessation Intervention for Patients with Asthma and COPD,ACEP25,QCDR Measure,Process,19.20264145809774,81.78,No,No,10.87,49.0,75.72,79.53,81.6,88.585,90.92,93.52,94.53,97.35,99.4,N,N,registrySinglePerformanceRate
Kidney Health Evaluation,488,eCQM,Process,17.46203172520052,19.34,No,No,0.13,2.38,5.41,8.2,11.11,14.065,18.03,23.57,31.46,44.44,72.7,N,N,singlePerformanceRate
Melanoma Reporting,397,Medicare Part B Claims,Process,2.273520800158349,99.21,Yes,No,84.0,86.0,88.0,90.0,92.0,94.0,96.0,98.0,99.0,100.0,100.0,Y,N,singlePerformanceRate
Hammer Toe Outcome,MEX5,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),25.926002417938133,27.99,No,No,0.35,2.03,4.71,9.69,12.82,19.75,28.19,38.1,50.0,65.22,100.0,Y,N,registrySinglePerformanceRate
Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients,320,MIPS CQM,Process,15.757061424186842,93.60,Yes,Yes,9.71,85.55,93.215,96.43,97.71,98.63,99.505,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Breast Cancer Screening,112,MIPS CQM,Process,26.993811843474045,69.16,No,No,1.2,29.56,45.87,57.89,67.87,76.47,81.94,87.64,95.31,100.0,100.0,N,N,singlePerformanceRate
Avoidance of Cerebral Hyperthermia for Procedures Involving Cardiopulmonary Bypass,AQI65,QCDR Measure,Outcome,19.171291842740807,87.59,No,No,31.08,55.275,72.235,81.58,99.395,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents,239,eCQM,Process,19.577304066625558,41.47,No,No,4.76,22.73,28.1,30.62,32.61,34.79,39.53,47.13,56.77,71.15,96.98,N,N,multiPerformanceRate
Sleep Apnea: Assessment of Adherence to Obstructive Sleep Apnea (OSA) Therapy.,279,MIPS CQM,Process,17.161845319553407,94.83,Yes,Yes,8.33,90.48,99.77,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low-Risk Surgery Patients,322,MIPS CQM,Efficiency,0.2858761405007603,0.03,No,No,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.2,Y,Y,singlePerformanceRate
Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients,406,Medicare Part B Claims,Process,22.28899894297143,9.03,Yes,Yes,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,3.85,30.43,94.12,Y,Y,singlePerformanceRate
Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity,177,MIPS CQM,Process,16.729059755316054,91.94,Yes,Yes,17.14,74.48,90.13,95.01,97.78,99.34,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Functional Status Change in Dizziness,FOTO6,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),15.81666968207697,73.44,No,No,40.0,54.55,58.33,62.5,67.78,76.32,79.92,83.4,86.415,93.1,100.0,Y,N,registrySinglePerformanceRate
Appropriate Treatment for Upper Respiratory Infection (URI),065,eCQM,Process,18.992091335122307,85.38,No,No,14.71,58.75,76.24,85.15,89.66,92.365,95.04,96.92,98.77,100.0,100.0,Y,N,singlePerformanceRate
Tunneled Hemodialysis Catheter Clinical Success Rate,RCOIR12,QCDR Measure,Outcome,12.397529184981709,78.48,No,No,44.94,54.55,73.81,78.05,79.91,83.33,85.08,86.33,87.61,88.51,91.0,Y,N,registrySinglePerformanceRate
Coronary Artery Disease (CAD): Beta-Blocker Therapy – Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF ≤ 40%),007,MIPS CQM,Process,9.865496412434705,92.77,Yes,Yes,57.43,77.27,86.12,90.48,93.43,97.37,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Melanoma Reporting,397,MIPS CQM,Process,10.000716169599112,98.37,Yes,No,84.0,86.0,88.0,90.0,92.0,94.0,96.0,98.0,99.0,100.0,100.0,Y,N,singlePerformanceRate
Report Turnaround Time: PET,ACRAD19,QCDR Measure,Outcome,12.301602614772056,9.58,No,No,0.1732,1.49,1.94,2.55,3.38,5.485,8.07,10.53,12.46,22.47,66.55,Y,Y,nonProportion
Appropriate Treatment of Psychosis and Agitation in the Emergency Department,ECPR52,QCDR Measure,Process,17.16895167458625,68.53,No,No,22.96,43.54,50.0,58.78,69.65,72.465,75.87,79.86,85.4,87.14,89.96,N,N,registrySinglePerformanceRate
Follow-Up Care for Children Prescribed ADHD Medication (ADD),366,eCQM,Process,22.15911452140065,45.02,No,No,8.82,20.0,31.88,35.9,38.03,40.455,43.48,50.0,58.62,86.67,100.0,N,N,multiPerformanceRate
Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD),008,MIPS CQM,Process,10.458222989052368,95.83,Yes,Yes,37.08,88.46,94.04,98.51,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Standard Benign Positional Paroxysmal Vertigo (BPPV) Management,AAO32,QCDR Measure,Process,0.0,0.00,Yes,No,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,Y,Y,registrySinglePerformanceRate
Adult Primary Rhegmatogenous Retinal Detachment Surgery: No Return to the Operating Room Within 90 Days of Surgery,384,MIPS CQM,Outcome,5.54498384540302,95.39,Yes,Yes,75.0,87.88,92.81,94.23,96.15,96.925,98.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Report Turnaround Time: Mammography,ACRAD25,QCDR Measure,Outcome,13.740071598874835,11.64,No,No,0.31,1.08,1.91,3.81,5.14,7.45,9.11,11.55,18.42,29.72,66.29,Y,Y,nonProportion
Breast Cancer Screening,112,Medicare Part B Claims,Process,25.0087531091942,82.37,No,No,1.53,50.0,72.92,81.08,88.0,91.8,95.74,98.95,100.0,100.0,100.0,N,N,singlePerformanceRate
Oncology: Medical and Radiation - Pain Intensity Quantified,143,eCQM,Process,27.297471447895106,84.60,Yes,No,84.0,86.0,88.0,90.0,92.0,94.0,96.0,98.0,99.0,100.0,100.0,Y,N,singlePerformanceRate
Documentation of Current Medications in the Medical Record,130,MIPS CQM,Process,21.745388244685632,91.38,Yes,Yes,4.13,70.82,94.2,98.38,99.68,99.99,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Rehabilitative Therapy Referral for Patients with Parkinson's Disease,293,MIPS CQM,Process,18.311401790425982,94.65,Yes,Yes,5.0,91.89,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Lung Cancer Reporting (Biopsy/Cytology Specimens),395,Medicare Part B Claims,Process,2.2510734868362823,99.47,Yes,No,84.0,86.0,88.0,90.0,92.0,94.0,96.0,98.0,99.0,100.0,100.0,Y,N,singlePerformanceRate
Psoriasis – Appropriate Assessment & Treatment of Severe Psoriasis,AAD15,QCDR Measure,Process,20.419509897263563,32.03,No,No,2.99,5.84,14.44,17.69,24.1,32.015,37.39,44.84,46.88,56.25,100.0,N,N,registrySinglePerformanceRate
Screening for Osteoporosis for Women Aged 65-85 Years of Age,039,MIPS CQM,Process,31.9445559630481,54.79,No,No,0.38,4.46,19.46,36.19,48.42,58.065,68.71,77.83,86.81,96.98,100.0,N,N,singlePerformanceRate
Mismatch Repair (MMR) or Microsatellite Instability (MSI) Biomarker Testing  Status,491,MIPS CQM,Process,20.24594898067668,81.02,No,No,6.82,53.66,66.57,73.4,79.76,85.88,90.96,98.37,100.0,100.0,100.0,Y,N,singlePerformanceRate
Total Knee or Hip Replacement: Venous Thromboembolic and Cardiovascular Risk Evaluation,351,MIPS CQM,Process,22.44480881739708,92.74,Yes,Yes,0.59,83.21,98.29,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Appropriate Treatment for Upper Respiratory Infection (URI),065,MIPS CQM,Process,9.915162665575949,94.84,Yes,Yes,55.1,84.39,93.395,96.125,97.42,98.54,99.525,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Cataract Surgery: Difference Between Planned and Final Refraction,389,MIPS CQM,Outcome,12.452271318942772,93.61,No,No,50.0,78.57,89.29,96.14,98.2,99.19,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Dementia: Safety Concern Screening and Follow-Up for Patients with Dementia,286,MIPS CQM,Process,13.738370600434965,95.16,Yes,Yes,47.06,82.51,99.24,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Lung Cancer Reporting (Biopsy/Cytology Specimens),395,MIPS CQM,Process,1.4532510198069888,99.77,Yes,No,84.0,86.0,88.0,90.0,92.0,94.0,96.0,98.0,99.0,100.0,100.0,Y,N,singlePerformanceRate
Assessment of Cognitive Impairment or Dysfunction for Patients with Parkinson's Disease,291,MIPS CQM,Process,21.33863266152816,91.00,Yes,Yes,17.96,62.03,92.53,99.19,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented,317,Medicare Part B Claims,Process,28.73224558024895,85.64,Yes,Yes,0.37,29.61,80.92,96.3,99.41,99.86,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Incidental Coronary Artery Calcification Reported on Chest CT,ACRAD36,QCDR Measure,Process,21.314097274759675,88.91,Yes,Yes,11.11,58.54,77.14,93.75,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Barrett's Esophagus,249,Medicare Part B Claims,Process,0.0,100.00,Yes,No,84.0,86.0,88.0,90.0,92.0,94.0,96.0,98.0,99.0,100.0,100.0,N,N,singlePerformanceRate
"Functional Status Change for Patients with Lower Leg, Foot or Ankle Impairments",219,MIPS CQM,Patient-Reported Outcome-Based Performance Measure (PRO-PM),23.342686351654905,70.12,No,No,15.62,38.0,46.15,56.52,64.71,71.31,79.82,84.21,100.0,100.0,100.0,Y,N,singlePerformanceRate
Hospital admissions or infectious complications within 30 days of prostate biopsy,AQUA8,QCDR Measure,Outcome,2.811468824514957,2.62,No,No,0.0,0.0,0.46,1.29,1.72,1.79,2.27,2.56,3.63,5.3,12.77,Y,Y,registrySinglePerformanceRate
Diabetes: Glycemic Status Assessment Greater Than 9%,001,MIPS CQM,Intermediate Outcome,23.473780647758787,25.75,No,No,1.0,10.0,20.0,30.0,40.0,50.0,60.0,70.0,80.0,90.0,99.0,Y,Y,singlePerformanceRate
Perioperative Anemia Management,AQI72,QCDR Measure,Process,5.12513073195288,98.82,Yes,Yes,66.67,99.25,99.81,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Radiology: Exposure Dose Indices Reported for Procedures Using Fluoroscopy,145,Medicare Part B Claims,Process,25.409546606716763,87.67,Yes,No,1.43,48.28,83.1,95.45,98.77,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
"Multi-strata weighted average for 3 CT Exam Types: Overall Percent of CT exams for which Dose Length Product is at or below the size-specific diagnostic reference level (for CT Abdomen-pelvis with contrast/single phase scan, CT Chest without contrast/single phase scan and CT Head/Brain without contrast/single phase scan)",ACRAD34,QCDR Measure,Outcome,13.2215845431157,85.36,No,No,36.45,68.25,82.05,83.07,85.17,87.58,92.01,93.34,95.61,97.77,99.92,Y,N,registryMultiPerformanceRate
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan,128,Medicare Part B Claims,Process,18.519594421478384,92.66,Yes,Yes,15.36,71.06,95.8,99.44,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Rheumatoid Arthritis (RA): Functional Status Assessment,178,MIPS CQM,Process,20.29851502921145,90.83,Yes,Yes,9.59,73.0,90.82,95.79,98.26,99.62,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD),008,eCQM,Process,10.595388588812,90.89,No,No,36.0,81.58,87.67,91.23,92.45,93.48,94.74,95.47,96.55,98.11,100.0,N,N,singlePerformanceRate
Radiology: Exposure Dose Indices Reported for Procedures Using Fluoroscopy,145,MIPS CQM,Process,24.982003767051435,87.21,Yes,No,2.73,46.47,80.89,94.53,98.79,99.76,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Childhood Immunization Status,240,eCQM,Process,16.42485711351794,30.82,No,No,1.38,8.1,15.065,21.3,26.69,30.91,34.95,39.56,44.405,52.1,73.81,N,N,singlePerformanceRate
Perioperative Temperature Management,424,MIPS CQM,Outcome,7.173872912178585,98.55,Yes,No,84.0,86.0,88.0,90.0,92.0,94.0,96.0,98.0,99.0,100.0,100.0,Y,N,singlePerformanceRate
Percentage of Patients Who Died from Cancer Receiving Systemic Cancer-Directed Therapy in the Last 14 Days of Life (lower score – better),453,MIPS CQM,Process,7.501220315129662,10.74,No,No,0.0,2.94,4.48,5.31,7.14,9.67,11.28,13.29,15.97,22.22,30.43,Y,Y,singlePerformanceRate
Patient-Centered Surgical Risk Assessment and Communication,358,MIPS CQM,Process,22.28563522988703,90.77,Yes,Yes,1.81,58.01,95.24,99.43,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Chlamydia Screening for Women,310,eCQM,Process,18.89272490074917,32.95,No,No,1.55,8.33,15.38,21.84,27.5,31.81,36.36,41.67,48.11,59.15,81.37,N,N,singlePerformanceRate
Skin Cancer: Biopsy Reporting Time - Clinician to Patient,AAD6,QCDR Measure,Process,22.51792827134038,91.86,Yes,Yes,1.51,82.84,96.32,98.35,99.33,99.77,100.0,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
"Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention - Evaluation of Footwear",127,MIPS CQM,Process,25.70419447054066,87.40,Yes,Yes,0.41,48.41,83.33,95.45,99.44,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Avoidance of Opioid Prescriptions for Closure and Reconstruction After Skin Cancer Resection,AAD18,QCDR Measure,Process,0.0,0.00,Yes,No,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,Y,Y,registryMultiPerformanceRate
Measuring the Value-Functions of Primary Care: Physician Level Continuity of Care Measure,ABFM12,QCDR Measure,Efficiency,22.836833496274085,83.83,No,No,15.32,47.57,61.9,76.05,92.22,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 20% OR Documentation of a Plan of Care.,141,MIPS CQM,Outcome,10.071500986517034,97.77,No,No,27.42,96.71,99.03,99.55,99.78,99.95,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Rheumatoid Arthritis (RA): Glucocorticoid Management,180,MIPS CQM,Process,17.621458116196383,91.87,Yes,Yes,0.17,75.2,88.7,92.14,98.05,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Cardiac Rehabilitation Patient Referral from an Outpatient Setting,243,MIPS CQM,Process,29.151762825670698,45.83,No,No,2.94,16.72,22.89,28.0,33.33,37.12,40.91,49.12,74.45,96.7,100.0,Y,N,singlePerformanceRate
Glaucoma – Intraocular Pressure Reduction,IRIS2,QCDR Measure,Intermediate Outcome,5.834031216928362,90.02,No,No,72.15,82.55,85.9,88.0,89.55,90.85,92.22,93.38,94.7,96.43,100.0,Y,N,registrySinglePerformanceRate
Screening for Osteoporosis for Women Aged 65-85 Years of Age,039,Medicare Part B Claims,Process,26.802148192306475,76.14,No,No,0.68,34.67,54.64,66.67,77.88,85.33,92.76,97.19,100.0,100.0,100.0,N,N,singlePerformanceRate
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan,128,eCQM,Process,29.157203651383885,47.09,No,No,1.58,16.62,21.41,25.78,30.92,37.175,45.55,61.49,83.39,95.39,100.0,N,N,singlePerformanceRate
Avoidance of Post-operative Systemic Antibiotics for Office-based Closures and Reconstruction After Skin Cancer Procedures,AAD16,QCDR Measure,Process,12.014389688062098,6.42,Yes,No,0.0,0.0,0.0,0.66,1.52,3.03,4.62,6.71,8.78,14.33,66.31,Y,Y,registryMultiPerformanceRate
Patient-Reported Experience with Anesthesia,AQI48,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),2.541780614710775,93.89,No,No,88.5,90.92,91.86,92.28,93.11,93.555,94.3,95.07,96.43,97.32,100.0,Y,N,registryMultiPerformanceRate
Acute Rib Fracture Numbering on ED Trauma Patients,QMM24,QCDR Measure,Process,24.226117679605352,76.15,No,No,31.0,41.5,52.0,55.0,66.5,82.385,98.0,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Syncope – Avoidance of admission for adult patients with low-risk syncope,ACEP60,QCDR Measure,Outcome,7.289950334983416,90.12,Yes,No,68.64,80.67,84.47,88.04,89.64,90.6,92.8,95.03,97.03,97.91,100.0,Y,N,registrySinglePerformanceRate
Functional Status Change for Patients with Shoulder Impairments,221,MIPS CQM,Patient-Reported Outcome-Based Performance Measure (PRO-PM),24.08475818878787,71.04,No,No,14.53,38.24,47.19,54.84,65.85,73.77,80.41,90.91,100.0,100.0,100.0,Y,N,singlePerformanceRate
Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older,415,MIPS CQM,Efficiency,5.328695144463552,97.23,Yes,Yes,70.83,93.85,96.47,97.44,98.21,98.85,99.4,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Controlling High Blood Pressure,236,Medicare Part B Claims,Intermediate Outcome,17.34430362157295,78.36,No,No,1.0,10.0,20.0,30.0,40.0,50.0,60.0,70.0,80.0,90.0,99.0,Y,N,singlePerformanceRate
Controlling High Blood Pressure,236,MIPS CQM,Intermediate Outcome,19.079769857918812,72.82,No,No,1.0,10.0,20.0,30.0,40.0,50.0,60.0,70.0,80.0,90.0,99.0,Y,N,singlePerformanceRate
Avoidance of Long-Acting (LA) or Extended-Release (ER) Opiate Prescriptions and Opiate Prescriptions for Greater Than 3 Days Duration for Acute Pain,ECPR55,QCDR Measure,Process,11.928161502318654,84.92,No,No,46.88,75.11,79.85,80.33,82.37,84.385,87.65,94.4,95.66,97.7,100.0,Y,N,registrySinglePerformanceRate
Use of ASPECTS (Alberta Stroke Program Early CT Score) for non-contrast CT Head performed for suspected acute stroke.,MEDNAX55,QCDR Measure,Process,17.489498822082325,91.69,Yes,No,40.0,82.61,88.99,96.48,98.03,100.0,100.0,100.0,100.0,100.0,100.0,N,N,registrySinglePerformanceRate
Adherence to Antipsychotic Medications For Individuals with Schizophrenia,383,MIPS CQM,Intermediate Outcome,10.521416552337726,95.95,No,No,49.33,87.69,96.32,97.96,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Radical Prostatectomy Pathology Reporting,250,Medicare Part B Claims,Process,0.0,100.00,Yes,No,84.0,86.0,88.0,90.0,92.0,94.0,96.0,98.0,99.0,100.0,100.0,N,N,singlePerformanceRate
"Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists",379,eCQM,Process,27.06109748944661,63.75,No,No,14.0,19.92,35.405,54.44,63.625,73.86,75.65,79.52,87.335,98.83,100.0,N,N,singlePerformanceRate
Children Who Have Dental Decay or Cavities,378,eCQM,Outcome,26.51589566270955,19.97,No,No,0.0,0.0,0.0,0.17,0.73,3.38,16.55,29.14,50.24,56.65,93.62,Y,Y,singlePerformanceRate
Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented,317,MIPS CQM,Process,35.2380703595231,68.66,No,No,0.12,14.23,28.16,41.53,66.93,89.4,97.18,99.82,100.0,100.0,100.0,N,N,singlePerformanceRate
Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery,191,eCQM,Outcome,9.213794784794716,95.98,Yes,No,38.22,92.57,95.18,96.62,97.54,98.23,98.81,99.25,100.0,100.0,100.0,Y,N,singlePerformanceRate
Functional Status Change for Patients with Hip Impairments,218,MIPS CQM,Patient-Reported Outcome-Based Performance Measure (PRO-PM),23.279404302458158,70.73,No,No,13.33,40.16,50.0,55.56,62.86,71.595,79.89,87.5,100.0,100.0,100.0,Y,N,singlePerformanceRate
Report Turnaround Time: CT,ACRAD18,QCDR Measure,Outcome,11.659310336669309,6.94,No,No,0.46,0.75,0.99,1.31,1.98,2.44,3.37,4.54,7.56,18.72,58.23,Y,Y,nonProportion
Heel Pain Treatment Outcomes for Adults,REGCLR1,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),26.481671687747664,43.80,No,No,0.42,6.31,19.11,27.14,35.9,43.69,50.47,60.38,68.37,78.95,100.0,Y,N,registrySinglePerformanceRate
Closing the Referral Loop: Receipt of Specialist Report,374,eCQM,Process,30.11983857557838,46.69,No,No,0.65,6.93,17.39,26.79,34.84,43.31,52.0,61.54,78.17,95.24,100.0,Y,N,singlePerformanceRate
Optimal Asthma Control,398,MIPS CQM,Outcome,25.301761354406285,86.84,No,No,7.77,57.65,80.48,91.86,95.54,99.15,100.0,100.0,100.0,100.0,100.0,Y,N,multiPerformanceRate
Appropriate Treatment for Patients with Stage I (T1c) - III HER2 Positive Breast Cancer,450,MIPS CQM,Process,12.568719740008122,88.52,No,No,51.06,72.22,78.69,80.95,86.84,92.06,97.96,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Oncology: Supportive Care Drug Utilization in Last 14 Days of Life,PIMSH9,QCDR Measure,Efficiency,5.217988639990596,5.41,No,No,0.0,0.0,2.4,3.3,3.6,4.0,4.6,5.35,7.05,12.05,23.4,Y,Y,registrySinglePerformanceRate
Arteriovenous Graft Thrombectomy Clinical Success Rate,RPAQIR14,QCDR Measure,Outcome,10.487837841073114,83.90,No,No,46.67,73.33,77.22,80.0,82.98,85.86,88.61,90.44,91.59,96.15,97.14,Y,N,registrySinglePerformanceRate
Percentage of Patients Who Died from Cancer Admitted to Hospice for Less than 3 days (lower score - better),457,MIPS CQM,Outcome,9.286342327322673,8.45,No,No,0.0,0.0,0.0,2.02,4.085,6.575,7.935,10.0,14.04,23.09,42.86,Y,Y,singlePerformanceRate
IVC Filter Management Confirmation,QMM16,QCDR Measure,Process,27.482697276163734,89.62,Yes,Yes,0.41,43.0,95.83,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Avoid Head CT for Patients with Uncomplicated Syncope,ECPR39,QCDR Measure,Process,14.102243806912798,86.31,No,No,48.37,64.61,77.59,79.21,83.88,88.43,96.61,97.85,99.07,99.8,100.0,Y,N,registrySinglePerformanceRate
Oncology: Hepatitis B Serology Testing and Prophylactic Treatment Prior to Receiving Anti-CD20 Targeting Drugs,PIMSH10,QCDR Measure,Process,25.21721125808259,58.28,No,No,2.0,20.0,34.5,44.7,56.7,62.95,71.4,75.0,80.0,88.6,100.0,Y,N,registrySinglePerformanceRate
Report Turnaround Time: Ultrasound (Excluding Breast US),ACRAD16,QCDR Measure,Outcome,7.586476031605782,4.84,No,No,0.36,0.72,0.955,1.22,1.575,2.19,3.085,4.43,6.12,10.33,44.12,Y,Y,nonProportion
Prostate Cancer Reporting: Complete Analysis,CAP38,QCDR Measure,Process,6.731507569734465,97.40,Yes,Yes,60.42,90.78,97.675,99.4,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients,406,MIPS CQM,Process,12.711473807185165,3.72,Yes,No,0.0,0.0,1.0,2.0,4.0,6.0,8.0,10.0,12.0,14.0,16.0,Y,Y,singlePerformanceRate
Adult Immunization Status,493,MIPS CQM,Process,23.258211368441177,23.70,No,No,0.02,0.24,2.28,7.43,13.21,18.76,24.97,31.88,37.39,53.12,100.0,N,N,multiPerformanceRate
Radical Prostatectomy Pathology Reporting,250,MIPS CQM,Process,0.21972653144790463,99.97,Yes,No,84.0,86.0,88.0,90.0,92.0,94.0,96.0,98.0,99.0,100.0,100.0,N,N,singlePerformanceRate
Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment,382,eCQM,Process,31.501149082746007,40.27,No,No,0.33,2.36,6.06,15.36,23.54,35.64,50.0,59.98,71.07,91.55,100.0,Y,N,singlePerformanceRate
Gout: Serum Urate Target,ACR14,QCDR Measure,Intermediate Outcome,13.93177103580658,60.19,No,No,24.64,43.93,49.78,53.57,58.51,61.36,63.06,66.67,70.365,75.14,98.78,Y,N,registrySinglePerformanceRate
Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy,326,MIPS CQM,Process,12.362030658191626,92.65,Yes,No,38.26,76.52,84.425,91.17,98.61,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Anesthesiology Smoking Abstinence,404,MIPS CQM,Intermediate Outcome,19.945944888693607,77.67,No,No,10.85,49.1,68.75,73.56,77.27,80.58,85.07,89.47,94.83,99.85,100.0,Y,N,singlePerformanceRate
Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older,050,MIPS CQM,Process,17.691634524624998,90.78,Yes,No,4.17,72.53,83.74,90.06,98.18,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Controlling High Blood Pressure,236,eCQM,Intermediate Outcome,17.359768094925062,66.23,No,No,5.56,45.71,55.17,61.16,65.32,68.735,71.94,75.31,79.31,84.74,98.95,Y,N,singlePerformanceRate
Barrett's Esophagus,249,MIPS CQM,Process,0.23101257864892616,99.97,Yes,No,84.0,86.0,88.0,90.0,92.0,94.0,96.0,98.0,99.0,100.0,100.0,N,N,singlePerformanceRate
Documentation of Current Medications in the Medical Record,130,eCQM,Process,20.80107465424877,86.93,Yes,Yes,3.4,60.64,80.58,88.72,92.95,95.66,97.45,98.61,99.46,99.91,100.0,Y,N,singlePerformanceRate
Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF ≤ 40%),118,MIPS CQM,Process,10.31470526142868,89.48,No,No,58.33,76.15,80.99,83.87,86.89,90.0,94.69,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD),005,eCQM,Process,9.77202186633924,83.44,No,No,48.0,73.56,77.57,80.65,82.61,84.21,86.14,88.24,90.48,94.43,100.0,N,N,singlePerformanceRate
Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 Through 17 Years,416,MIPS CQM,Efficiency,11.57886084338278,4.69,No,No,0.0,0.0,0.0,0.0,0.0,0.0,1.87,3.45,4.58,8.33,52.5,Y,Y,singlePerformanceRate
Skin Cancer: Biopsy Reporting Time - Pathologist to Clinician,440,MIPS CQM,Process,5.25306405740319,98.84,Yes,No,84.0,86.0,88.0,90.0,92.0,94.0,96.0,98.0,99.0,100.0,100.0,Y,N,singlePerformanceRate
Use of Quantitative Criteria for Oncologic FDG PET Imaging,ACRAD41,QCDR Measure,Process,31.65663996067437,84.86,Yes,Yes,0.03,12.37,86.69,97.87,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Use of High-Risk Medications in Older Adults,238,MIPS CQM,Process,3.6916547260100327,0.30,Yes,No,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,5.97,Y,Y,multiPerformanceRate
"Sepsis Management: Septic Shock: Lactate Level Measurement, Antibiotics Ordered, and Fluid Resuscitation",ACEP48,QCDR Measure,Process,14.913321222486205,83.00,No,No,17.1,71.67,78.085,81.475,84.145,85.28,87.61,90.325,93.04,94.835,97.87,N,N,registrySinglePerformanceRate
Functional Status Assessment for Total Hip Replacement,376,eCQM,Process,15.59566019851781,16.41,No,No,1.06,3.04,4.14,4.93,8.65,11.09,15.0,18.82,28.57,37.04,66.95,Y,N,singlePerformanceRate
HIV Viral Suppression,338,MIPS CQM,Outcome,11.435129427349867,93.82,No,No,38.04,78.78,90.91,93.7,96.97,98.61,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Tympanostomy Tubes: Comprehensive Audiometric Evaluation,AAO20,QCDR Measure,Process,21.536010644563646,78.95,No,No,19.16,39.33,67.45,81.265,83.39,86.805,88.62,89.975,94.135,96.71,98.22,N,N,registrySinglePerformanceRate
Diabetes: Glycemic Status Assessment Greater Than 9%,001,eCQM,Intermediate Outcome,28.578612328424896,42.70,No,No,2.385,13.46,18.485,23.02,27.54,32.915,40.275,51.68,73.2,94.35,99.44,Y,Y,singlePerformanceRate
Stroke and Stroke Rehabilitation: Thrombolytic Therapy,187,MIPS CQM,Process,11.547653099863632,96.54,Yes,Yes,35.32,90.24,98.36,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Adult Sinusitis: Antibiotic Prescribed for Acute Viral Sinusitis (Overuse),331,MIPS CQM,Process,30.807660576940147,32.83,No,No,0.0,0.0,0.0,5.0,11.9,23.945,38.24,56.0,68.09,78.0,92.75,Y,Y,singlePerformanceRate
"Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy - Neurological Evaluation",126,MIPS CQM,Process,31.465189649548318,80.13,Yes,Yes,0.76,19.31,54.0,81.42,96.23,99.55,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Use of Thyroid Imaging Reporting & Data System (TI-RADS) in Final Report to Stratify Thyroid Nodule Risk,MSN15,QCDR Measure,Process,12.412209484746343,96.92,Yes,Yes,11.68,96.34,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Falls: Screening for Future Fall Risk,318,eCQM,Process,34.4598281903334,64.10,No,No,0.15,6.22,25.73,43.96,60.91,75.96,86.31,93.92,98.07,99.66,100.0,Y,N,singlePerformanceRate
Closing the Referral Loop: Receipt of Specialist Report,374,MIPS CQM,Process,23.56336852555502,89.33,Yes,No,3.26,54.71,88.785,97.75,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Ankylosing Spondylitis: Controlled Disease Or Improved Disease Function,UREQA10,QCDR Measure,Outcome,30.042343307880817,33.91,No,No,0.35,1.17,1.25,8.73,19.5,28.0,41.56,42.73,66.07,78.23,88.0,Y,N,registrySinglePerformanceRate
Sepsis Management: Septic Shock: Lactate Clearance Rate of >=10%,ACEP30,QCDR Measure,Outcome,11.815652808825305,83.59,No,No,62.18,64.0,73.91,76.32,81.03,88.565,89.22,91.89,95.24,96.3,100.0,Y,N,registrySinglePerformanceRate
Psoriasis: Screening for Psoriatic Arthritis,AAD7,QCDR Measure,Process,13.21815023590948,92.11,Yes,Yes,40.62,77.55,86.96,93.33,95.95,97.715,98.81,99.57,99.79,100.0,100.0,Y,N,registrySinglePerformanceRate
Gastritis: Timely Helicobacter pylori Reporting,CAP28,QCDR Measure,Process,9.905750117278597,93.56,Yes,Yes,50.0,81.1,88.54,93.34,96.36,98.035,98.69,99.05,99.67,100.0,100.0,Y,N,registrySinglePerformanceRate
Continuation of Anticoagulation Therapy in the Office-based Setting for Closure and Reconstruction After Skin Cancer Resection Procedures,AAD17,QCDR Measure,Process,12.443625918517483,96.95,Yes,No,39.02,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,registryMultiPerformanceRate
Depression Remission at Twelve Months,370,eCQM,Outcome,12.193611980423082,12.72,No,No,0.78,2.37,3.85,5.52,7.32,9.15,11.63,14.0,18.14,27.54,51.89,Y,N,multiPerformanceRate
Assessment of Mood Disorders and Psychosis for Patients with Parkinson's Disease,290,MIPS CQM,Process,7.3090398851982785,98.31,Yes,Yes,47.62,97.3,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Ischemic Vascular Disease (IVD) All or None Outcome Measure (Optimal Control),441,MIPS CQM,Intermediate Outcome,21.943966955672213,47.79,No,No,9.24,16.61,31.15,38.82,43.08,47.425,52.78,57.3,64.0,71.79,100.0,Y,N,singlePerformanceRate
Vitamin D level: Effective Control of Low Bone Mass/Osteopenia and Osteoporosis: Therapeutic Level Of 25 OH Vitamin D Level Achieved,UREQA8,QCDR Measure,Outcome,25.412444372872297,56.61,No,No,12.5,26.07,33.94,43.4,44.59,58.03,63.48,78.19,83.71,86.97,99.46,Y,N,registrySinglePerformanceRate
ED Median Time from ED arrival to ED departure for all Pediatric ED Patients,ACEP51,QCDR Measure,Outcome,33.696170168996524,122.35,No,No,71.0,85.0,90.0,101.0,113.0,115.5,125.0,138.0,144.0,177.0,213.0,Y,Y,nonProportion
Screening for Social Drivers of Health,487,MIPS CQM,Process,44.62168581592107,43.32,No,No,0.03,0.13,0.25,0.81,7.29,18.75,61.9,99.09,100.0,100.0,100.0,Y,N,singlePerformanceRate
Screening for Osteoporosis for Men Aged 70 Years and Older,UREQA9,QCDR Measure,Process,16.69990410455848,27.38,No,No,0.81,7.7,12.13,16.79,22.02,27.265,34.03,35.39,37.93,48.23,69.3,N,N,registrySinglePerformanceRate
Elder Maltreatment Screen and Follow-Up Plan,181,MIPS CQM,Process,13.996766055904237,96.89,Yes,Yes,2.35,98.24,99.99,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
HIV Screening,475,eCQM,Process,17.14843511609166,18.72,No,No,0.12,1.5,3.49,6.1,9.98,14.71,20.0,25.0,31.37,40.27,80.06,N,N,singlePerformanceRate
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan,128,MIPS CQM,Process,25.09046010520721,86.90,Yes,Yes,2.04,40.84,80.65,94.23,98.24,99.76,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis,116,MIPS CQM,Process,16.924144812902533,89.95,Yes,No,11.43,64.96,86.36,91.38,94.74,96.14,98.69,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Preventive Care and Screening: Screening for Depression and Follow-Up Plan,134,Medicare Part B Claims,Process,15.924803100815586,94.93,Yes,Yes,8.16,86.58,99.19,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Adult Kidney Disease: Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy,489,MIPS CQM,Process,22.734065234575777,80.16,No,No,11.76,55.14,62.43,67.54,81.85,90.27,91.43,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Diabetes: Eye Exam,117,eCQM,Process,39.008537885097276,62.45,No,No,0.49,6.93,16.92,28.22,43.85,80.22,98.74,99.66,100.0,100.0,100.0,N,N,singlePerformanceRate
Functional Outcome Assessment,182,MIPS CQM,Process,25.630114458298006,92.08,Yes,Yes,0.12,91.71,99.79,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Biopsy Reporting Time to Clinician,CAP22,QCDR Measure,Process,16.750007843434048,89.58,Yes,Yes,30.0,64.8,74.79,93.28,95.95,97.31,98.34,98.93,99.49,100.0,100.0,Y,N,registrySinglePerformanceRate
Preventive Care and Screening: Screening for Depression and Follow-Up Plan,134,MIPS CQM,Process,23.51606922387561,89.24,Yes,Yes,0.08,61.68,84.5,97.71,99.78,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Diabetic Macular Edema - Loss of Visual Acuity,IRIS13,QCDR Measure,Outcome,1.314042683992972,99.26,Yes,Yes,95.0,97.85,98.81,99.21,99.46,99.765,100.0,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Advance Care Plan,047,MIPS CQM,Process,28.892059789657996,82.58,Yes,Yes,0.34,30.27,67.78,85.88,94.955,98.76,99.85,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Age-Related Hearing Loss: Comprehensive Audiometric Evaluation,AAO16,QCDR Measure,Process,20.419122843840878,77.12,No,No,12.5,46.325,58.335,71.08,77.765,83.33,87.03,90.06,94.335,98.885,100.0,Y,N,registrySinglePerformanceRate
Osteoporosis Management in Women Who Had a Fracture,418,MIPS CQM,Process,24.512396917343736,24.81,No,No,2.27,7.09,10.0,11.61,14.16,16.015,20.0,25.0,31.82,51.72,100.0,N,N,singlePerformanceRate
Dementia: Functional Status Assessment,282,MIPS CQM,Process,11.09402592895981,97.77,Yes,Yes,25.0,98.78,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Bunion Outcome - Adult and Adolescent,REGCLR3,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),29.537795843624878,28.16,No,No,0.47,1.82,3.94,7.69,10.325,17.86,21.75,36.21,57.54,72.41,100.0,Y,N,registrySinglePerformanceRate
Preventive Care and Screening: Screening for Depression and Follow-Up Plan,134,eCQM,Process,32.12077840978634,48.51,No,No,0.09,4.96,15.06,24.74,35.28,45.945,58.11,71.39,84.23,94.99,100.0,N,N,singlePerformanceRate
Appropriate Follow-up Recommendations for Ovarian-Adnexal Lesions using the Ovarian-Adnexal Reporting and Data System (O-RADS),QMM17,QCDR Measure,Process,40.422822102405085,62.98,No,No,0.63,2.0,9.91,17.41,70.72,78.53,89.135,99.07,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Diabetes: Glycemic Status Assessment Greater Than 9%,001,Medicare Part B Claims,Intermediate Outcome,15.1249307925172,11.02,No,No,1.0,10.0,20.0,30.0,40.0,50.0,60.0,70.0,80.0,90.0,99.0,Y,Y,singlePerformanceRate
Surgical Site Infection (SSI),357,MIPS CQM,Outcome,7.540148604731367,0.98,No,No,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.12,13.79,Y,Y,singlePerformanceRate
Dermatitis – Improvement in Patient-Reported Itch Severity,486,MIPS CQM,Patient-Reported Outcome-Based Performance Measure (PRO-PM),27.562706323923912,45.77,No,No,2.5,13.92,21.33,28.36,33.33,40.22,47.62,56.52,70.0,95.83,100.0,Y,N,singlePerformanceRate
Functional Status Change for Patients with Neck Impairments,478,MIPS CQM,Patient-Reported Outcome-Based Performance Measure (PRO-PM),23.31921722737784,67.95,No,No,23.81,34.94,46.67,52.5,59.26,66.67,75.19,83.8,97.725,100.0,100.0,Y,N,singlePerformanceRate
Non-Recommended Cervical Cancer Screening in Adolescent Females,443,MIPS CQM,Process,3.9443370369451127,1.74,Yes,No,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,3.18,6.97,16.67,Y,Y,singlePerformanceRate
Appropriate Foley catheter use in the emergency department,ACEP31,QCDR Measure,Process,25.627208423450014,76.83,No,No,19.89,27.79,52.59,81.58,86.62,89.275,90.55,91.415,93.695,95.015,99.71,Y,N,registrySinglePerformanceRate
Functional Status Change for Patients with Vestibular Dysfunction,HM7,QCDR Measure,Outcome,20.75324514666675,37.93,No,No,3.33,12.5,18.75,25.0,30.43,35.035,42.86,47.22,52.17,65.61,100.0,Y,N,registryMultiPerformanceRate
Appropriate follow-up interval based on pathology findings in screening colonoscopy,GIQIC23,QCDR Measure,Process,19.82005722788699,84.67,No,No,18.91,55.56,75.72,83.33,91.8,92.93,94.51,95.38,98.46,99.57,100.0,Y,N,registryMultiPerformanceRate
Prevention of Post-Operative Vomiting (POV) - Combination Therapy (Pediatrics),463,MIPS CQM,Process,2.903538582521347,99.23,Yes,No,84.0,86.0,88.0,90.0,92.0,94.0,96.0,98.0,99.0,100.0,100.0,Y,N,singlePerformanceRate
Optimizing Patient Exposure to Ionizing Radiation: Count of Potential High Dose Radiation Imaging Studies: Computed Tomography (CT) and Cardiac Nuclear Medicine Studies,360,MIPS CQM,Process,22.460373987242487,93.63,Yes,No,84.0,86.0,88.0,90.0,92.0,94.0,96.0,98.0,99.0,100.0,100.0,Y,N,singlePerformanceRate
"Avoidance of Chest X-ray in pediatric patients with Asthma, Bronchiolitis or Croup",ACEP61,QCDR Measure,Process,17.028184233919287,32.51,No,No,0.0,13.77,18.17,20.32,30.0,31.045,35.87,40.58,50.94,56.44,65.69,Y,Y,registrySinglePerformanceRate
Appropriate Testing for Pharyngitis,066,eCQM,Process,28.6136698448602,70.24,No,No,0.79,16.13,48.57,66.1,76.26,81.855,86.06,89.69,92.46,95.53,99.09,Y,N,singlePerformanceRate
Appropriate Testing for Pharyngitis,066,MIPS CQM,Process,14.461866293148496,93.57,Yes,Yes,25.21,83.315,94.87,96.94,98.07,98.63,99.09,99.415,100.0,100.0,100.0,Y,N,singlePerformanceRate
Sleep Apnea: Severity Assessment at Initial Diagnosis,277,MIPS CQM,Process,35.06902241723992,76.67,Yes,No,0.19,15.47,29.68,75.19,95.41,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
Improved Visual Acuity after Vitrectomy for Complications of Diabetic Retinopathy within 120 Days,IRIS58,QCDR Measure,Outcome,6.252762562455675,85.59,No,No,68.97,76.0,80.77,82.05,84.51,85.94,87.04,88.89,91.25,93.55,100.0,Y,N,registrySinglePerformanceRate
Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery,191,MIPS CQM,Outcome,4.158501928259923,98.35,Yes,Yes,72.76,95.52,97.97,98.85,99.42,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Dementia: Education and Support of Caregivers for Patients with Dementia,288,MIPS CQM,Process,14.203125504019694,96.39,Yes,Yes,13.33,95.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Immunizations for Adolescents,394,MIPS CQM,Process,24.112808978597776,36.17,No,No,2.5,9.09,15.0,21.65,27.72,31.415,36.11,40.48,51.67,75.27,100.0,N,N,multiPerformanceRate
Refractive Surgery: Patients with a postoperative uncorrected visual acuity (UCVA) of 20/20 or better within 30 days,IRIS23,QCDR Measure,Outcome,5.78959700912553,94.07,No,No,77.42,84.47,89.29,91.89,94.25,95.87,97.14,98.01,99.57,100.0,100.0,Y,N,registrySinglePerformanceRate
Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented,317,eCQM,Process,18.586538024485534,27.10,No,No,0.05,4.34,14.38,18.89,22.51,25.39,28.47,31.89,36.17,44.96,100.0,N,N,singlePerformanceRate
Use of High-Risk Medications in Older Adults,238,eCQM,Process,7.338206423432709,4.51,Yes,No,0.0,0.0,0.0,0.0,0.09,0.52,1.67,4.3,9.43,15.43,30.03,Y,Y,multiPerformanceRate
Appropriate Follow-up Imaging for Incidental Abdominal Lesions,405,Medicare Part B Claims,Process,37.50535296794312,61.18,No,No,1.67,9.305,14.29,24.745,50.0,73.42,83.665,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Tuberculosis Screening Prior to First Course of Biologic and/or Immune Response Modifier Therapy,176,MIPS CQM,Process,23.55790114541919,87.21,Yes,Yes,5.26,51.28,80.17,90.48,95.83,100.0,100.0,100.0,100.0,100.0,100.0,N,N,singlePerformanceRate
ED Median Time from ED arrival to ED departure for all Adult Patients,ACEP50,QCDR Measure,Outcome,47.80414095757764,178.64,No,No,99.0,128.0,141.0,148.0,159.0,169.0,188.0,195.0,212.0,248.0,326.0,Y,Y,nonProportion
Chest Pain – Avoidance of admission for adult patients with low-risk chest pain.,ACEP59,QCDR Measure,Outcome,8.619950375548232,91.16,Yes,No,60.81,78.53,83.74,88.29,90.68,92.47,96.4,97.42,99.01,99.96,100.0,Y,N,registrySinglePerformanceRate
Interpretation of CT Pulmonary Angiography (CTPA) for Pulmonary Embolism,ACRAD37,QCDR Measure,Process,13.356266071695256,96.28,Yes,Yes,27.69,95.32,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Stones: Urinalysis or Urine Culture Performed Before Surgical Stone Procedures,AQUA15,QCDR Measure,Process,17.689933012874867,86.67,No,No,11.32,60.0,76.84,86.17,89.89,92.59,97.1,97.81,99.03,100.0,100.0,Y,N,registrySinglePerformanceRate
Functional Status Change in Balance Confidence,FOTO5,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),15.357507891119342,57.90,No,No,5.88,38.71,47.83,54.26,57.14,59.575,63.25,65.48,68.54,75.0,84.0,Y,N,registrySinglePerformanceRate
Disease Activity Measurement for Patients with PsA,ACR12,QCDR Measure,Process,24.767020023171078,80.05,No,No,3.57,46.36,66.125,80.91,83.4,90.03,92.825,95.55,97.375,99.02,100.0,N,N,registrySinglePerformanceRate
Adult Sinusitis: Appropriate Choice of Antibiotic: Amoxicillin With or Without Clavulanate Prescribed for Patients with Acute Bacterial Sinusitis (Appropriate Use),332,MIPS CQM,Process,15.210521537310386,91.30,Yes,Yes,17.65,77.27,86.67,91.3,95.06,97.13,100.0,100.0,100.0,100.0,100.0,Y,N,singlePerformanceRate
Preventive Care and Screening: Screening for Depression and Follow-Up Plan,134SSP,MIPS CQM,Process,"",--,No,No,1.0,10.0,20.0,30.0,40.0,50.0,60.0,70.0,80.0,90.0,99.0,N,N,singlePerformanceRate
Controlling High Blood Pressure,236SSP,MIPS CQM,Intermediate Outcome,"",--,No,No,1.0,10.0,20.0,30.0,40.0,50.0,60.0,70.0,80.0,90.0,99.0,Y,N,singlePerformanceRate
Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%),001SSP,MIPS CQM,Intermediate Outcome,"",--,No,No,1.0,10.0,20.0,30.0,40.0,50.0,60.0,70.0,80.0,90.0,99.0,Y,Y,singlePerformanceRate
Breast Cancer Screening,112SSP,MIPS CQM,Process,"",--,No,No,1.0,10.0,20.0,30.0,40.0,50.0,60.0,70.0,80.0,90.0,99.0,N,N,singlePerformanceRate
